447 related articles for article (PubMed ID: 27446091)
1. Human Circulating and Tissue-Resident CD56(bright) Natural Killer Cell Populations.
Melsen JE; Lugthart G; Lankester AC; Schilham MW
Front Immunol; 2016; 7():262. PubMed ID: 27446091
[TBL] [Abstract][Full Text] [Related]
2. Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways.
Hudspeth K; Donadon M; Cimino M; Pontarini E; Tentorio P; Preti M; Hong M; Bertoletti A; Bicciato S; Invernizzi P; Lugli E; Torzilli G; Gershwin ME; Mavilio D
J Autoimmun; 2016 Jan; 66():40-50. PubMed ID: 26330348
[TBL] [Abstract][Full Text] [Related]
3. Human Lymphoid Tissues Harbor a Distinct CD69+CXCR6+ NK Cell Population.
Lugthart G; Melsen JE; Vervat C; van Ostaijen-Ten Dam MM; Corver WE; Roelen DL; van Bergen J; van Tol MJ; Lankester AC; Schilham MW
J Immunol; 2016 Jul; 197(1):78-84. PubMed ID: 27226093
[TBL] [Abstract][Full Text] [Related]
4. Tissue-resident Eomes(hi) T-bet(lo) CD56(bright) NK cells with reduced proinflammatory potential are enriched in the adult human liver.
Harmon C; Robinson MW; Fahey R; Whelan S; Houlihan DD; Geoghegan J; O'Farrelly C
Eur J Immunol; 2016 Sep; 46(9):2111-20. PubMed ID: 27485474
[TBL] [Abstract][Full Text] [Related]
5. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
Takahashi E; Kuranaga N; Satoh K; Habu Y; Shinomiya N; Asano T; Seki S; Hayakawa M
Scand J Immunol; 2007 Feb; 65(2):126-38. PubMed ID: 17257217
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell lytic activity and CD56(dim) and CD56(bright) cell distributions during and after intensive training.
Suzui M; Kawai T; Kimura H; Takeda K; Yagita H; Okumura K; Shek PN; Shephard RJ
J Appl Physiol (1985); 2004 Jun; 96(6):2167-73. PubMed ID: 14752119
[TBL] [Abstract][Full Text] [Related]
7. Role of chemokines in the biology of natural killer cells.
Maghazachi AA
Curr Top Microbiol Immunol; 2010; 341():37-58. PubMed ID: 20369317
[TBL] [Abstract][Full Text] [Related]
8. Interferon-γ production by tubulointerstitial human CD56
Law BMP; Wilkinson R; Wang X; Kildey K; Lindner M; Rist MJ; Beagley K; Healy H; Kassianos AJ
Kidney Int; 2017 Jul; 92(1):79-88. PubMed ID: 28396119
[TBL] [Abstract][Full Text] [Related]
9. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
Huth TK; Staines D; Marshall-Gradisnik S
J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
[TBL] [Abstract][Full Text] [Related]
10. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets.
Yu J; Mao HC; Wei M; Hughes T; Zhang J; Park IK; Liu S; McClory S; Marcucci G; Trotta R; Caligiuri MA
Blood; 2010 Jan; 115(2):274-81. PubMed ID: 19897577
[TBL] [Abstract][Full Text] [Related]
11. CD3(-)CD16(-)CD56(bright) immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer.
Gogali F; Paterakis G; Rassidakis GZ; Liakou CI; Liapi C
Thyroid; 2013 Dec; 23(12):1561-8. PubMed ID: 23721357
[TBL] [Abstract][Full Text] [Related]
12. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
[TBL] [Abstract][Full Text] [Related]
13. Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69
Marquardt N; Kekäläinen E; Chen P; Kvedaraite E; Wilson JN; Ivarsson MA; Mjösberg J; Berglin L; Säfholm J; Manson ML; Adner M; Al-Ameri M; Bergman P; Orre AC; Svensson M; Dahlén B; Dahlén SE; Ljunggren HG; Michaëlsson J
J Allergy Clin Immunol; 2017 Apr; 139(4):1321-1330.e4. PubMed ID: 27670241
[TBL] [Abstract][Full Text] [Related]
14. New miRNA Signature Heralds Human NK Cell Subsets at Different Maturation Steps: Involvement of miR-146a-5p in the Regulation of KIR Expression.
Pesce S; Squillario M; Greppi M; Loiacono F; Moretta L; Moretta A; Sivori S; Castagnola P; Barla A; Candiani S; Marcenaro E
Front Immunol; 2018; 9():2360. PubMed ID: 30374356
[TBL] [Abstract][Full Text] [Related]
15. Human CD56
Amand M; Iserentant G; Poli A; Sleiman M; Fievez V; Sanchez IP; Sauvageot N; Michel T; Aouali N; Janji B; Trujillo-Vargas CM; Seguin-Devaux C; Zimmer J
Front Immunol; 2017; 8():699. PubMed ID: 28674534
[TBL] [Abstract][Full Text] [Related]
16. CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation.
Romagnani C; Juelke K; Falco M; Morandi B; D'Agostino A; Costa R; Ratto G; Forte G; Carrega P; Lui G; Conte R; Strowig T; Moretta A; Münz C; Thiel A; Moretta L; Ferlazzo G
J Immunol; 2007 Apr; 178(8):4947-55. PubMed ID: 17404276
[TBL] [Abstract][Full Text] [Related]
17. CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation.
Béziat V; Duffy D; Quoc SN; Le Garff-Tavernier M; Decocq J; Combadière B; Debré P; Vieillard V
J Immunol; 2011 Jun; 186(12):6753-61. PubMed ID: 21555534
[TBL] [Abstract][Full Text] [Related]
18. CD56bright natural killer (NK) cells: an important NK cell subset.
Poli A; Michel T; Thérésine M; Andrès E; Hentges F; Zimmer J
Immunology; 2009 Apr; 126(4):458-65. PubMed ID: 19278419
[TBL] [Abstract][Full Text] [Related]
19. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
[TBL] [Abstract][Full Text] [Related]
20. Human Bone Marrow-Resident Natural Killer Cells Have a Unique Transcriptional Profile and Resemble Resident Memory CD8
Melsen JE; Lugthart G; Vervat C; Kielbasa SM; van der Zeeuw SAJ; Buermans HPJ; van Ostaijen-Ten Dam MM; Lankester AC; Schilham MW
Front Immunol; 2018; 9():1829. PubMed ID: 30186282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
